Evidence map›Paper›PMID 34294889›Full record

ArticleCell death and differentiation2022

De novo and cell line models of human mammary cell transformation reveal an essential role for Yb-1 in multiple stages of human breast cancer.

Sylvain Lefort, Amal El-Naggar, Susanna Tan, Shane Colborne, Gian Luca Negri, Davide Pellacani, Martin Hirst, Barry Gusterson, Gregg B Morin, Poul H Sorensen and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cell death and differentiation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Sylvain LefortTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
Amal El-NaggarDepartment of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-3202-6171
Susanna TanTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
Shane ColborneCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
Gian Luca NegriDepartment of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Davide PellacaniTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
Martin HirstCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
Barry GustersonInstitute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Gregg B MorinCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-8949-4374
Poul H SorensenDepartment of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. psor@mail.ubc.ca.
Connie J EavesTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada. ceaves@bccrc.ca.ORCID http://orcid.org/0000-0002-3452-1926
BC Cancer Agency · CAUniversity of British Columbia · CACanada's Michael Smith Genome Sciences Centre · CAUniversity of British Columbia Hospital · CAUniversity of Glasgow · GB

Funding

CIHR 143280Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) CRP-154482Michael Smith Foundation for Health Research (MSFHR) 17159
6 · The paper itself

Abstract

Breast cancer heterogeneity has made it challenging to identify mechanisms critical to the initial stages of their genesis in vivo. Here, we sought to interrogate the role of YB-1 in newly arising human breast cancers as well as in established cell lines. In a first series of experiments, we found that short-hairpin RNA-mediated knockdown of YB-1 in MDA-MB-231 cells blocked both their local tumour-forming and lung-colonising activity in immunodeficient mice. Conversely, upregulated expression of YB-1 enhanced the poor in vivo tumorigenicity of T47D cells. We then found that YB-1 knockdown also inhibits the initial generation in mice of invasive ductal carcinomas and ductal carcinomas in situ from freshly isolated human mammary cells transduced, respectively, with KRAS

Indexed as

Breast NeoplasmsAnimalsCell Line, TumorDNA HelicasesFemaleHumansMicePoly-ADP-Ribose Binding ProteinsRNA HelicasesRNA Recognition Motif ProteinsTranscription FactorsY-Box-Binding Protein 1DNA HelicasesG3BP1 protein, humanPoly-ADP-Ribose Binding ProteinsRNA HelicasesRNA Recognition Motif ProteinsTranscription FactorsY-Box-Binding Protein 1YBX1 protein, humanYbx1 protein, mouse

Identifiers

PMID34294889
PMCPMC8738742
OpenAlexW3185526368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.